Regulatory Professionals

Regulatory Affairs Recruitment

Close
  • Job Search
    • Vacancies
    • Our Services
      • Lifecycle Management
      • Regulatory Writing
      • Regulatory Submissions and Publishing
      • Regulatory CMC
      • Regulatory Clinical
      • Medical Devices
  • Candidates
    • Send Us Your CV
    • Downloads
    • Regulatory Glossary
    • Regulatory Professionals’ Pipeline Watch
    • Referral Scheme
    • Contracting
    • Permanent
    • EAA Regulations
  • Employers
    • Integrated Regulatory Outsourcing
    • Contract Staffing Solution
    • Permanent Staffing Solutions
    • Client Testimonials
  • About Us
    • News
    • CP Group
    • Work For Us
    • Privacy Policy
  • Contact Us
  • Account
Menu

takeda

Written by Stephen Smith
August 20, 2012

Generic Actos Launched by Mylan, Teva and Ranbaxy

Mylan, Teva and Ranbaxy announced on Friday that they have each launched generic forms of Takeda’s blockbuster type 2 diabetes drug Actos in the US. The generic drugmakers are sharing 180-day exclusivity for the generic versions of the branded medication, which receives in sales of roughly $2.7 billion a year across America. Actos (pioglitazone) is

Continue Reading

Written by Stephen Smith
May 24, 2012

EMA Accepts Takeda’s Diabetes Medication, Alogliptin, for Review

Takeda Pharmaceutical announced today that the European Medicines Agency (EMA) has agreed to review their type 2 diabetes treatment, alogliptin, a month after receiving a negative response for the therapy from the US FDA (Food and Drug Administration). The Japanese drug maker received confirmation of the acceptance of the proposal of a marketing authorisation application

Continue Reading

Written by Stephen Smith
April 26, 2012

US FDA Requests Additional Data on Takeda’s Alogliptin

Takeda Pharmaceuticals have suffered a key setback after US regulators rejected their type 2 diabetes therapy, alogliptin, and the fixed-dose combination of the medicine with Takeda’s Actos. Actos lost patent protection in 2011, and generic versions of the drug are anticipated to hit the marketplace later this year. The business received a second complete response

Continue Reading

Written by Daniel Patterson
October 27, 2011

PAS reverses NICE rejection of Takeda’s Mepact

  Takeda’s Mepact (mifamurtide) has been recommended by the National Institute for Health and Clinical Excellence (NICE) as a treatment for young patients with osteosarcoma, when it is made available to the NHS at reduced cost under a patient access scheme (PAS). In a Final Appraisal Determination (FAD) which reverses the negative FAD published by

Continue Reading

Categories

  • Industry News
  • Job Boards
  • Only Medics
  • Social Media
  • News
  • Awards
  • Company Info
  • Exhibition/Conference

Tags

Ablynx ABPI Almirall Alzheimer's Arena Pharmaceuticals Ariad Biogen Biogen Idec Cancer Research UK Carbon Neutral clinical research clinical trial Daiichi Sankyo deCODE EMA Enlight Biosciences Evotec Excaliard GSK Haemophilia Icon ICR Janssen Pharmaceuticals Job Digest Lunch Cancer Lundbeck Menarini Merck MSF National Online Recruitment Awards Networking Olympics oncology Paralympics Parexel PIPA plaxo Red Nose Day Referral Scheme Sankyo Sanofi Sunday Times survey UH Bristol Yale University

Like to Talk to a Consultant?

Call or email us directly and find out your next career step:
apply@regulatoryprofessionals.com or 0118 9522 797

The Clinical Professionals group of Companies.

CP Group

Job Alerts

Want personalised Job alerts delivered to you periodically?
Click the link below to register your details:



Job Alerts

Your Dashboard

Your account allows you to easily apply for roles, setup job alerts and bookmark positions to view later.

Click below to view your dashboard:

Dashboard

Our Offices

C/O Clinical Professionals,
33 Blagrave Street,
Reading, RG1 1PW, UK
0118 9522 797

C/O Clinical Professionals EU,
5 Old Bailey
London, EC4M 7BA, UK
+ 44 (0)207 822 1710

© 2022 Regulatory Professionals — All Rights Reserved
Facebook Twitter Google Linked In
Back to Top